<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04469439</url>
  </required_header>
  <id_info>
    <org_study_id>18-2280</org_study_id>
    <nct_id>NCT04469439</nct_id>
  </id_info>
  <brief_title>Impact of Sinus Surgery on Individuals With Cystic Fibrosis</brief_title>
  <official_title>The Impact of Sinus Surgery in the Era of Highly Effective Modulatory Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cystic Fibrosis Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be a prospective, observational study of patients who undergo endoscopic
      sinus surgery for cystic fibrosis-related chronic rhinosinusitis (CRS). Individuals who do
      not undergo surgery but are treated medically for CRS will also be enrolled to serve as a
      control group. Outcomes analyzed will include pulmonary, quality of life, and others.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in pulmonary function</measure>
    <time_frame>baseline, 3, 6, 9, 12 months</time_frame>
    <description>Pulmonary function will be measured using spirometry - the percent of predicted forced expiratory volume in the first second (ppFEV1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in days of inpatient hospitalization</measure>
    <time_frame>baseline, 3, 6, 9, 12 months</time_frame>
    <description>Days of inpatient hospitalization will be assessed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life</measure>
    <time_frame>baseline, 3, 6, 9, 12 months</time_frame>
    <description>Quality of life will be assessed using the 22-question SinoNasal Outcome test (range 0-110, with higher scores signifying worse quality of life)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life</measure>
    <time_frame>baseline, 3, 6, 9, 12 months</time_frame>
    <description>Quality of life will be assessed using the Cystic Fibrosis Questionnaire-Revised instrument (range 0-100, with higher scores signifying worse quality of life)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in olfaction</measure>
    <time_frame>baseline, 3, 6, 9, 12 months</time_frame>
    <description>Olfaction will be assessed using the Smell Identification Test (score range: 0-40, with higher scores demonstrated better olfactory ability)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Patient satisfaction regarding treatment for chronic rhinosinusitis</measure>
    <time_frame>at baseline</time_frame>
    <description>Satisfaction will be assessed using 5-point Likert scales, ranging from 1 to 5 with 1 signifying &quot;not important&quot; and 5 signifying &quot;very important&quot;</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Chronic Rhinosinusitis (Diagnosis)</condition>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Surgical group</arm_group_label>
    <description>Individuals with cystic fibrosis and chronic rhinosinusitis who undergo endoscopic sinus surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medical group</arm_group_label>
    <description>Individuals with cystic fibrosis and chronic rhinosinusitis who do not undergo endoscopic sinus surgery</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Specimens are collected
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects will be recruited from cystic fibrosis and otolaryngology outpatient clinics.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects between the ages of 18 years old (inclusive) and 99 years old (inclusive,
             subjects over the age of 89 will be recorded to be 89 years old).

          2. Diagnosed with cystic fibrosis as established by genetic testing combined with
             clinical assessment and/or sweat chloride

          3. Diagnosed with chronic rhinosinusitis by multidisciplinary sinusitis guidelines

          4. chronic rhinosinusitis symptoms persisting beyond initial medical treatment

          5. Counseled for endoscopic sinus surgery and ongoing medical therapy with each patient
             electing their preferred treatment

        Exclusion Criteria:

          1. Underwent endoscopic sinus surgery in past 12 months

          2. Will obtain follow up care at non-participating institutions

          3. Unable to complete follow-up surveys
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel M Beswick, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniel M Beswick, MD</last_name>
    <phone>720-848-7900</phone>
    <email>daniel.beswick@cuanschutz.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>James W Manor, MS</last_name>
    <phone>919-357-8030</phone>
    <email>james.manor@cuanschutz.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Colorado - Anschutz Medical Campus</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Daniel M Beswick, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 9, 2020</study_first_submitted>
  <study_first_submitted_qc>July 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2020</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Rhinosinusitis</keyword>
  <keyword>Cystic Fibrosis</keyword>
  <keyword>Endoscopic Sinus Surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Participant data will securely stored using REDCap software.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>REDCap</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://redcap.ucdenver.edu/</doc_url>
      <doc_comment>Study data will be collected and managed using REDCap (Research Electronic Data Capture). REDCap is a secure web application designed to support data capture for research studies, providing user-friendly web-based case report forms, real-time data entry validation (e.g. for data types and range checks), audit trails and an indirectly identified data export mechanism to common statistical packages.</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

